VistaGen Therapeutics, Inc.

NASDAQ:VTGN

3.12 (USD) • At close November 7, 2024
Bedrijfsnaam VistaGen Therapeutics, Inc.
Symbool VTGN
Munteenheid USD
Prijs 3.12
Beurswaarde 84,411,912
Dividendpercentage 0%
52-weken bereik 2.45 - 5.86
Industrie Biotechnology
Sector Healthcare
CEO Mr. Shawn K. Singh J.D.
Website https://www.vistagen.com

An error occurred while fetching data.

Over VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the

Vergelijkbare Aandelen

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

1.27 USD

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

0.382 USD

KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc.

KALV

11.18 USD

Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc.

COGT

10.05 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

23.3 USD

PepGen Inc. logo

PepGen Inc.

PEPG

5.63 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

9 USD

Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO

4.16 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)